Climb Bio Inc (NASDAQ: CLYM) kicked off on Friday, down -6.35% from the previous trading day, before settling in for the closing price of $1.26. Over the past 52 weeks, CLYM has traded in a range of $1.05-$9.21.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -40.44% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 41.18%. With a float of $58.19 million, this company’s outstanding shares have now reached $67.58 million.
In an organization with 18 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Climb Bio Inc (CLYM) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Climb Bio Inc is 13.89%, while institutional ownership is 76.30%. The most recent insider transaction that took place on Jun 20 ’25, was worth 1,540. In this transaction SVP, Finance & CAO of this company sold 1,242 shares at a rate of $1.24, taking the stock ownership to the 18,888 shares. Before that another transaction happened on Mar 20 ’25, when Company’s SVP, Finance & CAO sold 1,199 for $1.31, making the entire transaction worth $1,571. This insider now owns 15,130 shares in total.
Climb Bio Inc (CLYM) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 41.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.24% during the next five years compared to -40.44% drop over the previous five years of trading.
Climb Bio Inc (NASDAQ: CLYM) Trading Performance Indicators
Take a look at Climb Bio Inc’s (CLYM) current performance indicators. Last quarter, stock had a quick ratio of 14.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.37, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Climb Bio Inc (CLYM)
Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was better than the volume of 0.3 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 48.15%.
During the past 100 days, Climb Bio Inc’s (CLYM) raw stochastic average was set at 13.68%, which indicates a significant increase from 6.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.79% in the past 14 days, which was lower than the 71.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2494, while its 200-day Moving Average is $2.5629. However, in the short run, Climb Bio Inc’s stock first resistance to watch stands at $1.2531. Second resistance stands at $1.3261. The third major resistance level sits at $1.3627. If the price goes on to break the first support level at $1.1435, it is likely to go to the next support level at $1.1069. Assuming the price breaks the second support level, the third support level stands at $1.0339.
Climb Bio Inc (NASDAQ: CLYM) Key Stats
The company with the Market Capitalisation of 79.74 million has total of 67,576K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -73,900 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -20,780 K.
